Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Alin Megerdichian

Ophthalmology Loma Linda, CA Medical Doctor

NPI 1205417417 CMS profile 11429157

11234 Anderson St, Loma Linda, CA 92354

Open in the dashboard

General payments

$2,892

51 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alin Megerdichian of Loma Linda, CA is reported in the CMS Open Payments database as having received $2,892 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $454 10
2024 General $661 16
2023 General $1,688 20
2022 General $88 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alin Megerdichian
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Alin Megerdichian were reported at $454. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Alin Megerdichian Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $0 $205 $76–$534 $132
2022 $88 $266 $100–$678 $149
2023 $1,688 $308 $117–$745 $160
2024 $661 $340 $127–$846 $164
2025 $454 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Bausch & Lomb Americas Inc. $1,585 17 payments
  2. Alcon Vision LLC $639 17 payments
  3. Carl Zeiss Meditec USA, Inc. $176 3 payments
  4. Sight Sciences, Inc. $142 1 payment
  5. AbbVie, Inc. $91 3 payments
  6. Regeneron Healthcare Solutions, Inc. $87 3 payments
  7. Johnson & Johnson Surgical Vision, Inc. $70 4 payments
  8. Sun Pharmaceutical Industries Inc. $38 1 payment
  9. Amgen Inc. $35 1 payment
  10. ANI Pharmaceuticals, Inc. $30 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,761 45 payments
  2. Travel and Lodging $1,130 6 payments
Products named General payments · program years 2022–2025
  1. STELLARIS ELITE $1,530 15 payments
  2. enVista MX60 IOL $1,530 15 payments
  3. Trulign IOL $1,530 15 payments
  4. Crystalens Accommodating IOL (AT-52AO) $1,530 15 payments
  5. HYDRUS Microstent $359 11 payments
  6. IOLMaster 700 $168 2 payments
  7. QUATERA 700 $168 2 payments
  8. Clareon Ophthalmology $163 3 payments
  9. OMNI SURGICAL SYSTEM $142 1 payment
  10. Clareon Ophthalmology $102 2 payments
  11. Other $474 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record